Abstract
We will review nowadays trends in radionuclide therapy and new challenges in therapy respond assessment, theragnostics and radiotherapy planning. We will also mention a long-lasting problem of artefacts and new ways how to resolve them.
Nuclear medicine tools describing cellular and subcellular biological properties make it possible to detect tumor heterogeneity and identification of metabolic disarray typical for dedifferentiation. There is also a new insight into classical bone scintigraphy, e.g., early SPECT is a matter of interest and there are several new publications about this topic.
Last but not least is a new progress in quantification, we will also discuss current techniques in this area. EANM practical guidelines were published yet which can help physicians and scientists to perform a high-quality quantitative evaluation of radiopharmaceutical distribution.